Actuate Therapeutics, Inc. (ACTU) — 8-K Filings

8-K Filings (15)

• 8-K Filing — May 6, 2026
• Actuate Therapeutics Files 8-K — Nov 28, 2025 Risk: low
  Actuate Therapeutics, Inc. filed an 8-K on November 28, 2025, reporting an entry into a material definitive agreement and related financial statements/exhibits.
• 8-K Filing — Nov 21, 2025
• Actuate Therapeutics Enters Material Definitive Agreement — Sep 10, 2025 Risk: medium
  Actuate Therapeutics, Inc. announced on September 10, 2025, that it has entered into a material definitive agreement. The company, formerly known as Apotheca Th
• Actuate Therapeutics Enters Material Agreement, Files 8-K — Jun 26, 2025 Risk: medium
  Actuate Therapeutics, Inc. announced on June 25, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of
• Actuate Therapeutics Files 8-K — Jun 5, 2025 Risk: low
  Actuate Therapeutics, Inc. filed an 8-K on June 5, 2025, reporting events as of May 31, 2025. The filing primarily concerns Regulation FD disclosures and the su
• Actuate Therapeutics Files 8-K — Jun 2, 2025 Risk: low
  Actuate Therapeutics, Inc. filed an 8-K on June 2, 2025, reporting events as of May 31, 2025. The filing includes a Regulation FD Disclosure and Other Events, a
• Actuate Therapeutics Files 8-K on Security Holder Vote — May 23, 2025 Risk: low
  Actuate Therapeutics, Inc. filed an 8-K on May 23, 2025, reporting on a matter submitted to a vote of its security holders on May 22, 2025. The company, formerl
• Actuate Therapeutics Files 8-K — May 6, 2025 Risk: low
  Actuate Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting other events and financial statements. The company, formerly known as Apotheca Therapeutics, I
• Actuate Therapeutics Files 8-K for Material Agreement — Mar 28, 2025 Risk: medium
  Actuate Therapeutics, Inc. filed an 8-K on March 27, 2025, reporting the entry into a material definitive agreement and unregistered sales of equity securities.
• Actuate Therapeutics to be Acquired by 03 Life Sciences — Feb 7, 2025 Risk: medium
  Actuate Therapeutics, Inc. announced on February 7, 2025, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is
• Actuate Therapeutics Files 8-K — Dec 17, 2024 Risk: low
  Actuate Therapeutics, Inc. filed an 8-K on December 17, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
• Actuate Therapeutics Files 8-K — Nov 12, 2024 Risk: low
  Actuate Therapeutics, Inc. filed an 8-K on November 12, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, former
• Actuate Therapeutics Appoints BDO USA as New Auditor — Aug 19, 2024 Risk: low
  Actuate Therapeutics, Inc. announced on August 19, 2024, a change in its certifying accountant. The company has appointed BDO USA, LLP as its new independent re
• Actuate Therapeutics Files 8-K with Officer, Director, and Bylaw Updates — Aug 14, 2024 Risk: medium
  Actuate Therapeutics, Inc. filed an 8-K on August 14, 2024, reporting several key events. These include the departure of directors or certain officers, the elec

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX